<DOC>
	<DOCNO>NCT02163278</DOCNO>
	<brief_summary>The study perform assess safety , tolerability , pharmacokinetic ( PK ) pharmacodynamic ( PD ) property multiple oral dos DBPR108 healthy male subject .</brief_summary>
	<brief_title>A Multiple Ascending Dose Phase I Study DBPR108 Healthy Male Subjects</brief_title>
	<detailed_description>This study represent administration dipeptidyl peptidase 4 ( DPP4 ) inhibitor DBPR108 human evaluate safety , tolerability , pharmacokinetic ( PK ) pharmacodynamic ( PD ) property follow multiple oral dos healthy subject . DPP4 validate drug target treatment human type 2 diabetes . Objectives study assess safety tolerability , PKs PDs DBPR108 steady state administration multiple oral dos healthy male subject .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male suitable vein cannulation repeat venipuncture , must able swallow investigational product intact . Aged 20 45 year ( inclusive ) screen visit . Able provide write informed consent willing comply study protocol procedure restriction . Has body weight less 50 kg and/or body mass index ( BMI ) less 18.5 kg/m2 great equal 24 kg/m2 screen visit . Body mass index determine total body weight/height2 ( kg/m2 ) . Has creatinine clearance ( Ccr ) less 80 mL/min screening . Is good general health judge Investigator base routine medical history , vital sign , physical examination , ECG , laboratory test , urinalysis screen visit admission Day 1 . Normal ECG include ( 1 ) sinus rhythm , ( 2 ) pulse rate 45 90 bpm , ( 3 ) Corrected QT ( QTc ) interval equal less 450 m ( correct cf Bazett 1920 ) , ( 4 ) QRS interval le 110 m , ( 5 ) PR interval le 200 m , ( 6 ) morphology consistent healthy cardiac conduction function . Is normoglycemic defined fast glucose le 70 mg/dL ( 3.9 mmol/L ) great 99 mg/dL ( 5.5 mmol/L ) , base laboratory test screen admission Day 1 , know diabetes impair glucose tolerance ( Retesting fast glucose sample collect subject initial fast glucose value 100105 mg/dL Day 1 acceptable . However , retesting fast glucose value still great 99 mg/dL , subject shall exclude consider screenfailure ) . Has platelet count less 150,000/μL . Uses antihyperglycemic agent screen admission Day 1 . Has history presence disease condition know interfere absorption , distribution , metabolism , excretion drug screen visit admission Day 1 . Has clinically significant psychiatric , renal , hepatic , cardiovascular , gastrointestinal , neurologic disease screen admission Day 1 . Is smoker and/or use nicotinecontaining product within last 6 month prior screen current study and/or history alcohol abuse . Has donate blood participate another clinical study within 8 week Day 1 . Excessive intake caffeinecontaining drink food ( i.e. , coffee , tea , chocolate , PAOLYTA B Liq , WHISBIH Liq , cola [ 6 unit caffeine per day ] ) . One caffeine unit contain follow item : 1 ( 177.4 mL ) cup coffee , 2 ( 354.9 mL ) can cola , 1 ( 354.9 mL ) cup tea , ½ ( 118.3 mL ) cup energy drink ( e.g. , PAOLYTA B Liq WHISBIH Liq ) , 3 oz chocolate . Use drug cytochrome P450 enzymeinducing inhibit property within 4 week prior first administration investigational product . Has use prescription nonprescription medication ( except occasional use paracetamol nasal spray ) herbal remedy vitamins mineral within 2 week 5 halflives drug , whichever longer , prior dose end study . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration investigational product . Male subject unwilling use barrier contraception addition partner use another method contraception , duration study 3 month dose . Has positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCVAb ) , human immunodeficiency virus ( HIV ) . Has receive blood transfusion and/or HCV infection . Positive result screen drug abuse , alcohol , cotinine ( nicotine ) screen Day 1 . Involved plan conduct study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>DBPR108</keyword>
	<keyword>DPP4</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Glucagon-like peptide-1 ( GLP-1 )</keyword>
	<keyword>Incretins</keyword>
</DOC>